Vivoryon Therapeutics NV (VVY) — Cash Flow-to-Debt Ratio
Vivoryon Therapeutics NV (VVY) has a Cash Flow-to-Debt Ratio of -1.42x as of December 2025, meaning its operating cash flow of €-3.96 Million could theoretically repay -1% of its total liabilities (€2.79 Million) in one year. See Vivoryon Therapeutics NV (VVY) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Vivoryon Therapeutics NV Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Vivoryon Therapeutics NV across 15 annual periods. For the full cash flow conversion analysis, see Vivoryon Therapeutics NV (VVY) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Vivoryon Therapeutics NV (2011–2025)
Year-by-year debt coverage analysis for Vivoryon Therapeutics NV. Check Vivoryon Therapeutics NV (VVY) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.03x | €-8.46 Million | €2.79 Million | ▲ +46.2% |
| 2024 | -5.63x | €-19.17 Million | €3.40 Million | ▼ -18.9% |
| 2023 | -4.74x | €-21.54 Million | €4.55 Million | ▼ -5.9% |
| 2022 | -4.47x | €-21.79 Million | €4.87 Million | ▼ -216.4% |
| 2021 | -1.41x | €-11.26 Million | €7.96 Million | ▲ +64.4% |
| 2020 | -3.97x | €-14.01 Million | €3.53 Million | ▼ -9.3% |
| 2019 | -3.63x | €-11.61 Million | €3.20 Million | ▼ -46.3% |
| 2018 | -2.48x | €-6.99K | €2.82K | ▲ +62.3% |
| 2017 | -6.59x | €-12.12K | €1.84K | ▼ -197.8% |
| 2016 | -2.21x | €-13.26K | €5.99K | ▼ -4.4% |
| 2015 | -2.12x | €-12.15K | €5.73K | ▼ -10.2% |
| 2014 | -1.92x | €-10.59K | €5.51K | ▼ -138.9% |
| 2013 | -0.80x | €-8.53 Million | €10.60 Million | ▲ +69.0% |
| 2012 | -2.59x | €-12.04 Million | €4.64 Million | ▲ +24.8% |
| 2011 | -3.45x | €-14.32 Million | €4.15 Million | — |